Nexalin Q2 FY26 net loss widens 42% to $2.24 million; revenue drops 83% to $12,161
NXL•Q2 FY26 results
Nexalin posted a net loss of USD 2.24 million, widening 42% year over year, as revenue slid 83% to USD 12,161.
Operating loss widened 39% to USD 2.25 million, while total operating expenses rose 35% to USD 2.26 million.
Expense changes and business updates
Research and development spending more than doubled to USD 564,480 on higher costs tied to the FDA insomnia clinical trial.
Professional fees jumped 128% to USD 407,444, reflecting higher accounting and legal costs tied to the PONM acquisition.
Nexalin completed the PONM acquisition, initiated its FDA-cleared Gen-3 HALO insomnia trial, and ended June 30 with cash of USD 1.01 million.
